Citi and RBC Capital upgrade Danaher on bioprocessing recovery
Analysts cite reaffirmed fiscal 2026 guidance and easing headwinds as key drivers for the upgrades to the Washington-headquartered firm.
Wall Street analysts have renewed their focus on Danaher Corporation (NYSE:DHR), with Citi and RBC Capital resuming coverage in May 2026 and assigning positive ratings to the stock. The move signals growing confidence among institutional investors regarding the company’s position in the bioprocessing sector and its ability to navigate recent market headwinds.
Citi initiated its renewed coverage on May 26, 2026, with a Buy rating and a $230 price target. The bank highlighted Danaher’s reaffirmation of its fiscal 2026 core growth guidance, delivered during the company’s first-quarter earnings report. Citi noted that the firm remains well-positioned to capitalise on improving industry conditions and sustained demand across its life sciences portfolio.
RBC Capital had resumed coverage earlier in the month, on May 14, 2026, assigning an Outperform rating and a $200 price target. The firm projects that a sustained rebound in bioprocessing activity, combined with easing company-specific challenges and improving end-market demand, could enable Danaher to achieve 6 per cent revenue growth by 2027.
The upgrades come as institutional interest in the company remains robust. Data from the first quarter of 2026 indicates that 110 hedge funds held positions in Danaher. The firm is also listed among the top 10 stocks owned by members of Congress, reflecting its prominence in institutional portfolios.
Danaher Corporation is headquartered in Washington, D.C. The company operates across the life sciences and industrial technology sectors, providing tools and services that support scientific research and manufacturing processes. The renewed analyst optimism underscores expectations for a recovery in the broader bioprocessing market.
